Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 67.92 0.16% 0.11
ALNY closed down 0.09 percent on Wednesday, May 22, 2019, on 50 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ALNY trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.16%
Oversold Stochastic Weakness 0.16%
Slingshot Bearish Bearish Swing Setup 0.07%
Wide Bands Range Expansion 0.07%
Oversold Stochastic Weakness 0.07%
NR7 Range Contraction 3.13%
NR7-2 Range Contraction 3.13%
Wide Bands Range Expansion 3.13%
Oversold Stochastic Weakness 3.13%
NR7 Range Contraction 0.56%

Older signals for ALNY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Hemophilia Spinal Muscular Atrophy Huntington's Disease Treatment Of Hemophilia Alnylam Pharmaceuticals Therapeutic Gene Modulation Deficiency Hemoglobinopathies Hypercholesterolemia Acute Intermittent Porphyria
Is ALNY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 124.215
52 Week Low 60.27
Average Volume 1,011,949
200-Day Moving Average 84.2193
50-Day Moving Average 83.2184
20-Day Moving Average 74.8285
10-Day Moving Average 68.585
Average True Range 3.5016
ADX 37.01
+DI 10.3971
-DI 30.7229
Chandelier Exit (Long, 3 ATRs ) 82.34519999999999
Chandelier Exit (Short, 3 ATRs ) 76.3148
Upper Bollinger Band 91.0224
Lower Bollinger Band 58.6346
Percent B (%b) 0.28
BandWidth 43.282706
MACD Line -5.0147
MACD Signal Line -4.6904
MACD Histogram -0.3243
Fundamentals Value
Market Cap 6.22 Billion
Num Shares 91.7 Million
EPS -5.12
Price-to-Earnings (P/E) Ratio -13.24
Price-to-Sales 159.14
Price-to-Book 9.35
PEG Ratio -0.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 71.71
Resistance 3 (R3) 71.58 70.15 71.06
Resistance 2 (R2) 70.15 69.16 70.22 70.84
Resistance 1 (R1) 68.98 68.54 69.57 69.11 70.63
Pivot Point 67.55 67.55 67.84 67.62 67.55
Support 1 (S1) 66.38 66.56 66.97 66.51 64.99
Support 2 (S2) 64.95 65.94 65.02 64.78
Support 3 (S3) 63.78 64.95 64.56
Support 4 (S4) 63.91